Novo Nordisk Teams With OpenAI to Speed Drug Development
Novo Nordisk said on Tuesday it will partner with OpenAI to use artificial intelligence across drug discovery, manufacturing, and commercial operations. The Wegovy and Ozempic maker will start pilot programs across research, development, and business units. It plans full integration by the end of 2026. The move comes as Novo tries to regain ground on Eli Lilly in the fast-growing weight-loss drug market.
AI Plan Extends Beyond the Lab
Novo said the partnership will use OpenAI’s technology to analyse complex datasets and identify promising drug candidates. At the same time, the company expects the tools to improve manufacturing efficiency. The plan also covers supply chains, distribution, and broader corporate operations. In turn, Novo is tying AI to both scientific work and day-to-day execution across the business.
Across the industry, drugmakers already use AI to handle slower parts of development. Those tasks include finding clinical trial participants, choosing study sites, and preparing regulatory filings. Even so, executives still say the technology has not yet solved the harder challenge of discovering major new molecules. That gap keeps expectations high, but it also keeps pressure on results.
Against that backdrop, Novo is looking for ways to move faster in obesity treatment. Lilly won U.S. approval this month for its weight-loss pill Foundayo. That approval came after Novo launched oral Wegovy in January. Can a wider AI push help Novo narrow the gap in one of pharma’s fiercest races?
Read More: OpenAI Acquires Hiro Finance to Boost AI Financial Planning Tools
Productivity, Hiring, and Safeguards
Novo said OpenAI will also help train its global workforce and raise AI literacy across departments. Chief Executive Mike Doustdar said the goal is not to replace scientists. Instead, he said the company wants to strengthen how they work and lift output across teams. As a result, Novo is presenting the partnership as a productivity drive, not a staffing overhaul.
Doustdar said the agreement is not designed to reduce Novo’s current workforce. Rather, he said AI should help employees work faster and more effectively. That could limit how quickly the company needs to hire in the future. Shortly after taking over last year, Doustdar announced a restructuring that cut 9,000 jobs, making the issue especially sensitive.
Novo did not disclose the financial terms of the deal. Still, it said the partnership includes strict data protection, governance, and human oversight. The company added that the agreement builds on existing AI work with other technology partners and research organisations. OpenAI Chief Executive, Sam Altman, said the collaboration could help accelerate scientific discovery, improve global operations, and shape future patient care.
Conclusion
Novo Nordisk has partnered with OpenAI to apply AI across drug development, manufacturing, and commercial operations. The company also plans to train staff and complete integration by the end of 2026. The key takeaway is that AI is becoming a central tool in how major drugmakers compete and improve efficiency.